Pharma BD Deal Intelligence
Novartis AG / Regulus Therapeutics
2025 · Acquisition/Merger · $1.7B · Complete
Announcement Sentiment
100
Strongly positive
Outcome Score
62
Largely worked — most objectives met.
Novartis acquired Regulus Therapeutics for $1.7B for kidney disease miR-17 inhibitor.
Key facts
- Announced Apr 30, 2025
- Closed Jun 30, 2025
- Deal value $1.7B
- Deal type Acquisition/Merger
- Therapeutic area Nephrology
- Key assets farabursen
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals